| Authors: |
Nolain P; Novo Nordisk A/S, Søborg, Denmark., Fugger M; Novo Nordisk A/S, Søborg, Denmark., Hellinghus BT; Novo Nordisk A/S, Søborg, Denmark., Hilgendorf I; Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Virchow Klinikum, Charité-Universitaetsmedizin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany., Højen JF; Novo Nordisk A/S, Søborg, Denmark., Libby P; Heart and Vascular Institute, Mass General Brigham, Harvard Medical School, Boston, MA, USA., Liuzzo G; Department of Cardiovascular and Pulmonary Sciences, Catholic University of Sacred Heart, Rome, Italy; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Matter CM; Department of Cardiology, Zurich University Hospital, Zurich, Switzerland., Tuttle KR; Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Nephrology Division, University of Washington School of Medicine, Seattle, WA, USA., Ridker PM; Center for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: pridker@bwh.harvard.edu. |
